Frankfurt
12.08.24 | 15:29
0,048 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.08.24 | JP Jenkins Ltd: Destiny Pharma to Deliver Presentation at the European Society of Clinical Microbiology and Infectious Disease conference on XF-73 Nasal Gel and the Use of Post-Operative Antibiotics in Cardio-vascula | 399 | EQS Group (EN) | JP Jenkins Ltd
Destiny Pharma to Deliver Presentation at the European Society of Clinical Microbiology and Infectious Disease conference on XF-73 Nasal Gel and the Use of Post-Operative... ► Artikel lesen | |
| 14.08.24 | JP Jenkins Ltd: Destiny Pharma initiates research to explore XF drug potential for CF | 390 | EQS Group (EN) | JP Jenkins Ltd
Destiny Pharma initiates research to explore XF drug potential for CF 14-Aug-2024 / 11:20 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen | |
| 13.08.24 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 13.08.2024 | 665 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 13.08.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 13.08.2024ISIN NameCA44053J4090 HORIZON... ► Artikel lesen | |
| 13.08.24 | JP Jenkins Ltd: Destiny Pharma plc shares now trading on JP Jenkins | 307 | EQS Group (EN) | JP Jenkins Ltd
Destiny Pharma plc shares now trading on JP Jenkins 13-Aug-2024 / 09:36 GMT/BST
The issuer is solely responsible for the content of this announcement.
13th Aug... ► Artikel lesen | |
| DESTINY PHARMA Aktie jetzt für 0€ handeln | |||||
| 13.08.24 | XFRA D89: AUSSETZUNG/SUSPENSION | 243 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILDESTINY PHARMA PLC... ► Artikel lesen |
5 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SKINBIOTHERAPEUTICS | 0,177 | 0,00 % | SkinBioTherapeutics - Notice of IMC Shareholder Presentation | ||
| VOR BIOPHARMA | 0,890 | 0,00 % | Pre-market Movers: Vor Biopharma, Worthington Steel, Surf Air Mobility, Nano Labs, Protagenic Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET).In the Green Vor Biopharma Inc. (VOR) is up over 109% at $1.16.
Worthington... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 40,330 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors | - If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors -
- Decision from European Commission expected in the third... ► Artikel lesen | |
| VERVE THERAPEUTICS | 11,255 | 0,00 % | BMO Capital stuft Verve Therapeutics nach Eli Lilly-Übernahme herab | ||
| QIAGEN | 41,175 | -0,13 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,410 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,380 | 0,00 % | ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today? | ||
| KYMERA THERAPEUTICS | 45,720 | 0,00 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
| ITEOS THERAPEUTICS | 10,020 | 0,00 % | iTeos Therapeutics Inc.: iTeos Therapeutics Announces Its Intention to Wind Down Operations | - Board of Directors intends to cease operations - Company to focus efforts on selecting best path to deliver near-term value to shareholders - Exploring potential asset sales including EOS-984, EOS-215... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 9,550 | 0,00 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| KEROS THERAPEUTICS | 13,510 | 0,00 % | Keros Therapeutics, Inc.: Keros Announces Return of $375 Million in Excess Capital to Stockholders | LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| EVOTEC | 7,174 | -0,31 % | Evotec Aktie mit Verkaufssignal: Konter oder Sturz auf 5 Euro? | Die Evotec Aktie hat am Donnerstag ein charttechnisches Verkaufssignal ausgelöst. Mit einem XETRA-Schlusskurs von 6,568 Euro fiel der Kurs um mehr als vier Prozent und unterschritt dabei mehrere relevante... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 13,050 | 0,00 % | Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies | - New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings -- Ongoing pivotal trial and FDA Type C meeting provide... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,310 | 0,00 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |
DESTINY PHARMA PLC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,048 Euro.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DESTINY PHARMA PLC finden Sie auf Wallstreet Online.